Study of Dose Adjustment From Levothyroxine to a New Levothyroxine Sodium Test Formulation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01916304|
Recruitment Status : Completed
First Posted : August 5, 2013
Results First Posted : July 20, 2015
Last Update Posted : July 20, 2015
|Condition or disease||Intervention/treatment||Phase|
|Hypothyroidism||Drug: Levothyroxine sodium new formulation||Phase 2|
The drug being tested in this study is a new sodium formulation of levothyroxine. Levothyroxine (L-Thyroxine Christiaens®) is used in the treatment of hypothyroidism. This study will investigate the effect of switching subjects taking levothyroxine to a new levothyroxine sodium formulation.
The results of this study will be used to provide instructions to general practitioners and endocrinologists assisting patients on levothyroxine hormone substitution in performing the switch to the new formulation.
The study will enroll approximately 90 patients. Patients receiving the same daily dose of L-Thyroxine Christiaens® during the past 6 weeks and with serum thyroid stimulating hormone (TSH) levels between 0.4-2.5 mU/L will be switched to the equivalent daily dose of the new formulation of levothyroxine. After the switch, patients will be followed up after 2 (± 2 weeks) and 4 months (± 4 weeks).
All participants will be asked to take a daily dose at the same time each day throughout the study.
This study will be conducted in Belgium. Participants will make 3 to 4 visits to the clinic.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||101 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Multicentre, Open-label Switch Study to Investigate the Necessity of Dose Adjustment After Switching From L-Thyroxine Christiaens® to the New Levothyroxine Sodium Test Formulation in (Near) Total Thyroidectomised Patients.|
|Study Start Date :||July 2013|
|Actual Primary Completion Date :||June 2014|
|Actual Study Completion Date :||June 2014|
Experimental: Levothyroxine sodium new formulation
Levothyroxine (25-225 μg), tablets, orally, once daily for up to 12 to 20 weeks. Dose administered depends on the thyroid stimulating hormone level.
Drug: Levothyroxine sodium new formulation
- Percentage of Participants That Do Not Need a Change of Dose [ Time Frame: 2 months (± 2 weeks) after switch to sodium formulation. ]Dose change was determined by physician according to their clinical judgement.
- Magnitude of the Change in Daily Dose Needed [ Time Frame: 2 months (± 2 weeks) after switch to sodium formulation. ]Magnitude was determined via a change table which provides the percentage of participants that needed a change in Daily Dose (μg/day) of -25 μg, -12.5 μg, -6.25 μg, -5.35 μg, 0 μg or +12.5 μg.
- Percentage of Participants That Obtained a Thyroid Stimulating Hormone (TSH) Between 0.4-2.5 mU/L [ Time Frame: Month 4 (± 4 weeks) after inclusion into study. ]Blood samples were collected and samples were analyzed according to the local Quality System.
- Absolute Serum Thyroid Stimulating Hormone Values [ Time Frame: Baseline, Month 2 (± 2 weeks) and Month 4 (± 4 weeks) after inclusion into study. ]Blood samples were collected and samples were analyzed according to the local Quality System.
- Relative Percent Change From Baseline in Serum Thyroid Stimulating Hormone [ Time Frame: Baseline, Month 2 (± 2 weeks) and Month 4 (± 4 weeks) after inclusion into study. ]Blood samples were collected and samples were analyzed according to the local Quality System. A negative change from Baseline indicated improvement.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01916304
|Study Director:||Medical Responsible||Takeda|